Osimertinib success in locally advanced EGFR-mutated NSCLC

Share :
Published: 3 Jun 2024
Views: 89
Rating:
Save
Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA

Dr Suresh Ramalingam speaks to ecancer at ASCO 2024 about results from the LAURA study which evaluated osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated non-small cell lung cancer.

He explains that patients were enroled within 6 weeks of chemotherapy and radiation as long as they did not have disease progression and were randomised 2:1 osimertinib versus placebo.

Dr Ramalingam reports that the progression-free survival was 39.1 months with osimertinib vs 5.6 months with placebo establishing this treatment as a new standard of care.